GAO Report Finds Policy Gaps in Drug Scheduling Decisions by FDA and DEA
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
What happened
A recent Government Accountability Office report found that the Drug Enforcement Administration and the Food and Drug Administration need more comprehensive policies for drug-scheduling decisions. The report stated that while the agencies' decisions aligned with recent recommendations from the Department of Health and Human Services, it also identified gaps in the written policies governing the process. Chief Administrative Law Judge Derek C. Julius ordered the GAO report admitted into the hearing record.
Why it matters
The scrutiny centers on the federal marijuana rescheduling proceeding. The lack of clear, consistent written standards raises fundamental questions about how the agencies evaluate evidence and determine a substance's classification under the Controlled Substances Act.
Who's involved
- Food and Drug AdministrationGovernment agency jointly scrutinized for policy gaps in drug-scheduling decisions
- Drug Enforcement AdministrationFederal law enforcement agency jointly scrutinized for policy gaps in drug-scheduling decisions
- Department of Health & Human ServicesGovernment department whose recommendations guide the operational decisions of the Drug Enforcement Administration
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Food and Drug AdministrationSpeculative
The Food and Drug Administration might face increased costs related to regulatory compliance due to identified policy gaps.
Keep exploring
The entities involved
-
Food and Drug Administration
government organization in Nonthaburi, Thailand
-
Drug Enforcement Administration
United States federal law enforcement agency
-
Department of Health & Human Services
government department in the state of Victoria, Australia